| Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer M Hall, G Peters Advances in cancer research 68, 67-108, 1996 | 1051 | 1996 |
| Copy number signatures and mutational processes in ovarian carcinoma G Macintyre, TE Goranova, D De Silva, D Ennis, AM Piskorz, M Eldridge, ... Nature genetics 50 (9), 1262-1270, 2018 | 380 | 2018 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 370 | 2017 |
| Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial M Procter, TM Suter, E De Azambuja, U Dafni, V Van Dooren, ... Journal of Clinical Oncology 28 (21), 3422-3428, 2010 | 329 | 2010 |
| Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. M Hall, S Bates, G Peters Oncogene 11 (8), 1581-1588, 1995 | 305 | 1995 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 253 | 2018 |
| Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled … JA Bridgewater, SA Pugh, T Maishman, Z Eminton, J Mellor, A Whitehead, ... The lancet oncology 21 (3), 398-411, 2020 | 190 | 2020 |
| Cdk2‐dependent phosphorylation of Id2 modulates activity of E2A‐related transcription factors E Hara, M Hall, G Peters The EMBO journal, 1997 | 183 | 1997 |
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis … AR Clamp, EC James, IA McNeish, A Dean, JW Kim, DM O'Donnell, ... The Lancet 394 (10214), 2084-2095, 2019 | 178 | 2019 |
| Neuropilin‑1 as a new potential SARS‑CoV‑2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID‑19 J Davies, HS Randeva, K Chatha, M Hall, DA Spandidos, E Karteris, ... Molecular medicine reports 22 (5), 4221-4226, 2020 | 167 | 2020 |
| An update on PARP inhibitors for the treatment of cancer S Benafif, M Hall OncoTargets and therapy, 519-528, 2015 | 152 | 2015 |
| Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations TI Goonewardene, MR Hall, GJS Rustin The lancet oncology 8 (9), 813-821, 2007 | 127 | 2007 |
| Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma … IB Vergote, A Jimeno, F Joly, D Katsaros, C Coens, E Despierre, C Marth, ... Journal of clinical oncology 32 (4), 320-326, 2014 | 122 | 2014 |
| Targeted anti-vascular therapies for ovarian cancer: current evidence M Hall, C Gourley, I McNeish, J Ledermann, M Gore, G Jayson, T Perren, ... British journal of cancer 108 (2), 250-258, 2013 | 95 | 2013 |
| British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice C Fotopoulou, M Hall, D Cruickshank, H Gabra, R Ganesan, C Hughes, ... European Journal of Obstetrics & Gynecology and Reproductive Biology 213 …, 2017 | 89 | 2017 |
| A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer IA McNeish, JA Ledermann, L Webber, L James, SB Kaye, M Hall, G Hall, ... Annals of oncology 25 (10), 1988-1995, 2014 | 86 | 2014 |
| Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report AFC Okines, RE Langley, LC Thompson, SP Stenning, L Stevenson, ... Annals of oncology 24 (3), 702-709, 2013 | 85 | 2013 |
| A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant … AM Oza, M Estevez-Diz, EM Grischke, M Hall, F Marmé, D Provencher, ... Clinical Cancer Research 26 (18), 4767-4776, 2020 | 84 | 2020 |
| ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive … C Marth, I Vergote, G Scambia, W Oberaigner, A Clamp, R Berger, ... European Journal of Cancer 70, 111-121, 2017 | 80 | 2017 |
| OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal … DM Provencher, CJ Gallagher, WR Parulekar, JA Ledermann, ... Annals of Oncology 29 (2), 431-438, 2018 | 76 | 2018 |
